This includes, for example, acetylcholinesterase activity, which is clinically used in AD pharmacotherapy with a limited efficacy rate, and monoamine oxidases circulating levels, which are also used as targets in Parkinson’s disease (PD) treatments with a limited clinical success rate. The gene discussed is ACHE; the disease is Alzheimer disease.